This Project Grant award from the National Institute of Biomedical Imaging and Bioengineering (NIBIB) under the Discovery and Applied Research for Technological Innovations to Improve Human Health (CFDA 93.286) program provides $586,967 to Case Western Reserve University to develop a theranostic agent, PSMA-1-PC413, for fluorescence-guided surgery and photodynamic therapy (PDT) to treat prostate cancer.
The goal is to use the prostate-specific membrane antigen (PSMA) biomarker to target a fluorescent and photosensitive agent to prostate tumors. This will allow surgeons to better visualize and remove cancerous tissue during prostatectomy, while also using PDT to eliminate any remaining non-visible or non-resectable cancerous cells. The project aims to improve surgical efficacy, prolong progression-free survival, and reduce morbidity associated with prostate cancer treatment. The research will be conducted in mouse models and an orthotopic canine prostate cancer model to assess the efficacy of the theranostic approach prior to potential clinical translation.
Generated 1/28/25, 8:23 AM